Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF

Bone Marrow Transplantation

Volumn 42, Issue 6, 2008, Pages 431-432

  Hsia, C C ^a   Linenberger, M ^b   Howson Jan, K ^a   Mangel, J ^a   Chin Yee, I H ^a   Collins, S ^a   Xenocostas, A ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; BONE MARROW BIOPSY; CANCER RISK; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; CYTOFLUOROMETRY; DONOR; DRUG EXPOSURE; DRUG MEGADOSE; FATIGUE; HLA MATCHING; HUMAN; HYPERNATREMIA; LETTER; LEUKAPHERESIS; LEUKOENCEPHALOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIBLING; SIDE EFFECT; SKIN ABSCESS;

GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; TIME FACTORS;

EID: 53149128351     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.205     Document Type: Letter

References (10)

1. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: An overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40: 185-192.
2. Makita K, Ohta K,Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661-665.
3. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: Report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
4. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 76-77.
5. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651-652.
6. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: Ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46: 422-433.
7. Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ. HLA associations with leukemia. Blood 1987; 70: 227-332.
8. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
9. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31-34.
10. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33-36.